Abstract:We report the development of novel cannabinergic probes that can stabilize the cannabinoid receptors (CBRs) through tight binding interactions. Ligand design involves the introduction of select groups at a judiciously chosen position within the classical hexahydrocannabinol template (monofunctionalized probes). Such groups include the electrophilic isothiocyanato, the photoactivatable azido, and the polar cyano moieties. These groups can also be combined to produce bifunctionalized probes potentially capable of interacting at two distinct sites within the CBR-binding domains. These novel compounds display remarkably high binding affinities for CBRs and are exceptionally potent agonists. A key ligand (27a, AM11245) exhibits exceptionally high potency in both in vitro and in vivo assays and was designated as "megagonist," a property attributed to its tight binding profile. By acting both centrally and peripherally, 27a distinguishes itself from our previously reported "megagonist" AM841, whose functions are restricted to the periphery.The Supporting Information is available free of charge at <a class="ext-link" href="/doi/10.1021/acs.jmedchem.0c02053?goto=supporting-info">https://pubs.acs.org/doi/10.1021/acs.jmedchem.0c02053</a>.Experimental procedures, spectroscopic, analytical, and physical data for 12a–b, 13a–b, 14a–c, 15a–c, 16a–c, 17a–c, 18a–c, 19a–c, 20a–c, 21a–c, 22a–c, 23a–c, 24a–c, 25a–c, 26a–c, and 27a–c; saturation binding curves using [3H]CP-55,940 for CB1 and CB2 receptors pre-incubated with the 25a–c, 26a–c, 27a–c, 31c, 32c, 33c, and 34c; and HPLC traces of 25a, 26c, 27b, and 31c (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c02053/suppl_file/jm0c02053_si_001.pdf">PDF</a>).Molecular formula strings and biochemical data of 25a–c, 26a–c, 27a–c, 31c, 32c, 33c, and 34c (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c02053/suppl_file/jm0c02053_si_002.csv">CSV</a>)This article has not yet been cited by other publications.

Design, Synthesis and Biological Evaluation of CB1 Cannabinoid Receptor Ligands Derived from the 1,5-Diarylpyrazole Scaffold

Design, Synthesis, And Sar Studies Of Heteroarylpyrimidines And Heteroaryltriazines As Cb2r Ligands

Design, syntheses, structure-activity relationships and docking studies of coumarin derivatives as novel selective ligands for the CB2 receptor.

Structure–Affinity Relationships and Structure–Kinetic Relationships of 1,2-Diarylimidazol-4-carboxamide Derivatives as Human Cannabinoid 1 Receptor Antagonists

Modulating the affinity and signaling bias of cannabinoid receptor 1 antagonists

In-silico designing and characterization of binding modes of two novel inhibitors for CB1 receptor against obesity by classical 3D-QSAR approach

Computational Investigation on the Binding Modes of Rimonabant Analogs with CB1 and CB2

Development of Yin-Yang ligand for cannabinoid receptors

In silico investigation of interactions between human cannabinoid receptor-1 and its antagonists

Motifs in Natural Products as Useful Scaffolds to Obtain Novel Benzo[ d]imidazole-Based Cannabinoid Type 2 (CB2) Receptor Agonists

Rational design of cannabinoid type-1 receptor allosteric modulators: Org27569 and PSNCBAM-1 hybrids

Synthesis and biological evaluation of a new class of multi-target heterocycle piperazine derivatives as potential antipsychotics

In silico mapping of allosteric ligand binding sites in type-1 cannabinoid receptor

Synthesis and Biological Activity of Chiral Dihydropyrazole: Potential Lead for Drug Design

Structure-Activity Relationship Studies of Coumarin-like Diacid Derivatives As Human G Protein-Coupled Receptor-35 (hgpr35) Agonists and a Consequent New Design Principle.

The progress of small molecules against cannabinoid 2 receptor (CB2R)

Novel Functionalized Cannabinoid Receptor Probes: Development of Exceptionally Potent Agonists

Design, synthesis and biological evaluation of novel scaffold benzo[4,5]imidazo [1,2-a]pyrazin-1-amine: Towards adenosine A2A receptor (A2A AR) antagonist

Design, synthesis and biological evaluation of novel pyrazolopyrimidone derivatives as potent PDE1 inhibitors

New role of phenothiazine derivatives as peripherally acting CB1 receptor antagonizing anti-obesity agents

Pharmacological evaluation of new constituents of "Spice": synthetic cannabinoids based on indole, indazole, benzimidazole and carbazole scaffolds